Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Expression”

163 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 163 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06198751
What this trial is testing

Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 104
Testing effectiveness (Phase 2)UnknownNCT05957757
What this trial is testing

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Who this might be right for
Non-Muscle Invasive Bladder CancerHER2
RenJi Hospital 20
Not applicableLooking for participantsNCT07630402
What this trial is testing

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Who this might be right for
Breast Cancer With Low to Intermediate HER2 Expression
University of Rochester 20
Large-scale testing (Phase 3)Looking for participantsNCT06340568
What this trial is testing

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Who this might be right for
Endometrial Cancer
BioNTech SE 480
Not applicableLooking for participantsNCT06127979
What this trial is testing

Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 42
Post-approval studies (Phase 4)UnknownNCT05861635
What this trial is testing

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Who this might be right for
Breast CancerNeoadjuvant Therapy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 42
Testing effectiveness (Phase 2)Looking for participantsNCT07523529
What this trial is testing

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Who this might be right for
Advanced UnresectableMetastatic
Beijing Biotech 72
Not applicableStudy completedNCT05695859
What this trial is testing

99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy

Who this might be right for
Breast Cancer Female
Tomsk National Research Medical Center of the Russian Academy of Sciences 24
Testing effectiveness (Phase 2)Study completedNCT00479674
What this trial is testing

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Duke University 41
Early research (Phase 1)Study completedNCT05203497
What this trial is testing

Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2.

Who this might be right for
Breast Cancer Female
Tomsk National Research Medical Center of the Russian Academy of Sciences 30
Testing effectiveness (Phase 2)Looking for participantsNCT05403242
What this trial is testing

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Who this might be right for
Advanced Gastroesophageal Adenocarcinoma
Chinese PLA General Hospital 42
Not applicableStudy completedNCT01446185
What this trial is testing

Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients

Who this might be right for
Breast Cancer
Genomic Health®, Inc. 100
Large-scale testing (Phase 3)Looking for participantsNCT07315750
What this trial is testing

Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Gastric Carcinoma
RemeGen Co., Ltd. 555
Testing effectiveness (Phase 2)Looking for participantsNCT06031584
What this trial is testing

BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Who this might be right for
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd. 42
Large-scale testing (Phase 3)UnknownNCT04400695
What this trial is testing

RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 366
Testing effectiveness (Phase 2)UnknownNCT05018676
What this trial is testing

ARX788 in Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer With Low Expression of HER2
Fudan University 54
Not applicableLooking for participantsNCT06289517
What this trial is testing

PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression

Who this might be right for
Neoplasms
Peking University First Hospital 30
Not applicableNot Yet RecruitingNCT06950671
What this trial is testing

Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study

Who this might be right for
Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage III+1 more
Rahma Esam Salama Esawi 1
Not applicableActive Not RecruitingNCT03503799
What this trial is testing

Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer

Who this might be right for
Primary Invasive Breast CancerEstrogen Receptor Positive TumorHuman Epidermal Growth Factor Receptor 2 Negative Tumor
North Eastern German Society of Gynaecological Oncology 1,191
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Load More Results